| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc (LGND) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. LGND is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 161.3K | $35.72M | - | |
| Dir | 44.0K | $9.74M | - | |
| Dir | 33.8K | $7.48M | - | |
| Dir | 32.8K | $7.25M | - | |
| Other | 30.8K | $6.82M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2018 | Patel Sunil | Director | Sale+OE | 42,287 | $240.05 | $10,150,808.29 | -63.3% | |
| Jul 2, 2018 | Kozarich John W61 | Director | Sell | 2,500 | $207.48 | $518,699.25 | -8.0% | |
| Jun 4, 2018 | Lamattina John L | Director | Sale+OE | 4,000 | $194.51 | $778,038.80 | -16.0% | |
| May 15, 2018 | Higgins John L66 | Chief Executive Officer | Sale+OE | 12,405 | $179.97 | $2,232,490.64 | -10.4% | |
| May 10, 2018 | Foehr Matthew W72 | President And COO | Sale+OE | 8,881 | $167.63 | $1,488,686.51 | -8.1% | |
| Apr 2, 2018 | Kozarich John W61 | Director | Sell | 2,500 | $160.43 | $401,062.50 | -7.5% | |
| Mar 12, 2018 | Sabba Stephen L | Director | Sell | 622 | $180.73 | $112,414.06 | -2.3% | |
| Mar 9, 2018 | Aryeh Jason | Director | Sell | 7,500 | $175.73 | $1,317,993.85 | -4.4% | |
| Mar 5, 2018 | Lamattina John L | Director | Sale+OE | 3,335 | $160.90 | $536,603.83 | -13.7% | |
| Feb 27, 2018 | Davis Todd C77 | Director | Sell | 17,170 | $152.37 | $2,616,244.31 | -12.6% |